Literature DB >> 8790509

Cascade testing for the identification of carriers of cystic fibrosis.

S Holloway1, D J Brock.   

Abstract

It has been suggested that cascade testing, in which relatives of a person affected with cystic fibrosis (CF) are tested for carrier status, is preferable to screening individuals in the general population. This idea was examined by calculating the number of relatives requiring testing, assuming that it is necessary to identify all those of reproductive age no more distantly related to the proband than second cousins. Two hypothetical programmes were used, in each of which only blood relatives of an affected proband were tested and subsequent analysis applied to relatives of those with a positive result. If started in the grandparental generation, cascade testing of about 28 relatives for each proband would detect 86.4% of carriers in the family. If only carried out for the parental generation and their descendants, testing of about 35 relatives for each proband would detect 92.1% of carriers in the family. If cascade testing were restricted to the second cousin level, however, these programmes would only detect between 8 and 24% of all carrier couples. This contrasts with the 50% detection rate that has already been demonstrated for antenatal CF screening.

Entities:  

Mesh:

Year:  1994        PMID: 8790509     DOI: 10.1177/096914139400100305

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  5 in total

1.  Estimating the efficacy and efficiency of cascade genetic screening.

Authors:  M Krawczak; D N Cooper; J Schmidtke
Journal:  Am J Hum Genet       Date:  2001-06-26       Impact factor: 11.025

2.  Costs, effects, and savings of screening for cystic fibrosis gene carriers.

Authors:  M F Wildhagen; H B Hilderink; J G Verzijl; J B Verheij; L Kooij; T Tijmstra; L P ten Kate; J D Habbema
Journal:  J Epidemiol Community Health       Date:  1998-07       Impact factor: 3.710

Review 3.  Carrier screening in the community.

Authors:  D J Brock
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

4.  Cystic fibrosis heterozygote screening in 5,161 pregnant women.

Authors:  D R Witt; C Schaefer; P Hallam; S Wi; B Blumberg; A Fishbach; J Holtzman; S Kornfeld; R Lee; L Nemzer; R Palmer
Journal:  Am J Hum Genet       Date:  1996-04       Impact factor: 11.025

5.  Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening.

Authors:  Kenneth Offit; Kaitlyn A Tkachuk; Zsofia K Stadler; Michael F Walsh; Hector Diaz-Zabala; Jeffrey D Levin; Zoe Steinsnyder; Vignesh Ravichandran; Ravi N Sharaf; Melissa K Frey; Steven M Lipkin; Mark E Robson; Jada G Hamilton; Joseph Vijai; Semanti Mukherjee
Journal:  J Clin Oncol       Date:  2020-01-10       Impact factor: 50.717

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.